Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Samsell B, Moore M, Bertasi G, Spinato S, Bernardello F, Rebaudi A, Sfasciotti GL, Powers R. Are bone allografts safe and effective for today's dental practitioner? Dentistry. 2014 Nov 3;4(9):1000260. doi: 10.4172/2161-1122.1000260
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Goyal RK, Williams DH, Sansgiry SS, Essien J. Awareness and perceived usefulness of the website designed to facilitate informed health insurance purchase decisions. TPHJ. 2010 Jul;62(3):8-11.